Keywords: Chelsea Therapeutics, Northera, FDA, Re-filing, USA, Hypotension, Celgene, Share buyback
Chelsea Thera to re-file Northera NDA with existing data; Celgene share buyback
Article | 21 February 2013
Chelsea Therapeutics International (Nasdaq: CHTP) saw its shares more than double to $1.61 in pre-market trading yesterday, as the company announced ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
